physicians must perform molecular monitoing regularly for successful outcomes in cml
Published 6 years ago • 96 plays • Length 0:51Download video MP4
Download video MP3
Similar videos
-
1:22
session overview: lifestyle medicine to improve patient/practitioner wellbeing and disease outcomes
-
3:23
molecular characteristics associated with increased risk of disease progression in smm
-
2:03
prognostic significance of molecular mrd in npm1-mutated aml treated with venetoclax-based therapy
-
4:27
cml management in resource limited countries
-
1:03
an insight into the sequencing of immunotherapies in adults with all
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:42
optimal sequencing of immunotherapies to improve outcomes for patients with multiple myeloma
-
9:25
mgus diagnosis: a step-by-step approach
-
3:03
outcomes of patients with richter's transformation without prior chemoimmunotherapy for cll/sll
-
2:32
emergency nursing at king's college hospital
-
1:43
keynote-667: pembrolizumab for children and young adults with classical hodgkin lymphoma
-
2:45
continuity of care for patients with hematological predispositions to aml
-
2:18
a cost per responder analysis of cilta-cel vs physician's choice in lenalidomide-refractory mm
-
0:48
evolving treatment goals in cml
-
3:46
the current landscape of treatment for frail myeloma patients at relapse & challenges in this space
-
1:44
patient reported outcomes in myeloid malignancies
-
3:16
improving upon the standard of care for patients with richter’s transformation
-
0:37
upcoming studies investigating linvoseltamab in myeloma
-
4:22
the role of mrd in aml
-
3:10
the importance of nutrition in hematology and cancer care
-
1:14
promising novel agents in aml: menin inhibitors